DE69523295T2 - Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung - Google Patents

Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung

Info

Publication number
DE69523295T2
DE69523295T2 DE69523295T DE69523295T DE69523295T2 DE 69523295 T2 DE69523295 T2 DE 69523295T2 DE 69523295 T DE69523295 T DE 69523295T DE 69523295 T DE69523295 T DE 69523295T DE 69523295 T2 DE69523295 T2 DE 69523295T2
Authority
DE
Germany
Prior art keywords
ketamine
nasal
detoxification
pain control
ocular use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69523295T
Other languages
English (en)
Other versions
DE69523295D1 (de
Inventor
Stuart L Weg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69523295D1 publication Critical patent/DE69523295D1/de
Application granted granted Critical
Publication of DE69523295T2 publication Critical patent/DE69523295T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
DE69523295T 1994-02-25 1995-02-24 Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung Expired - Lifetime DE69523295T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/201,756 US5543434A (en) 1994-02-25 1994-02-25 Nasal administration of ketamine to manage pain
PCT/US1995/002418 WO1995022965A2 (en) 1994-02-25 1995-02-24 Nasal and ocular administration of ketamine to manage pain and for detoxification

Publications (2)

Publication Number Publication Date
DE69523295D1 DE69523295D1 (de) 2001-11-22
DE69523295T2 true DE69523295T2 (de) 2002-07-11

Family

ID=22747152

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69523295T Expired - Lifetime DE69523295T2 (de) 1994-02-25 1995-02-24 Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung

Country Status (11)

Country Link
US (1) US5543434A (de)
EP (1) EP0751766B1 (de)
JP (1) JP4729148B2 (de)
AT (1) ATE206913T1 (de)
CA (1) CA2184077C (de)
DE (1) DE69523295T2 (de)
DK (1) DK0751766T3 (de)
ES (1) ES2165910T3 (de)
MX (1) MX9603633A (de)
PT (1) PT751766E (de)
WO (1) WO1995022965A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025925A1 (en) * 1995-02-24 1996-08-29 Weg Stuart L Nasal and ocular administration of ketamine to manage pain and for detoxification
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
CA2230690C (en) * 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6197830B1 (en) * 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040034107A1 (en) * 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
NZ524396A (en) * 2000-07-31 2003-09-26 Nycomed Danmark As Fentanyl composition for nasal administration comprising water as a solvent
US6948492B2 (en) * 2000-08-15 2005-09-27 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
ATE415155T1 (de) 2001-05-24 2008-12-15 Alexza Pharmaceuticals Inc Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20030129234A1 (en) * 2001-07-06 2003-07-10 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone
US9820982B2 (en) 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
AU2002361742A1 (en) * 2001-12-18 2003-06-30 Alexza Molecular Delivery Corporation Parental analgesic formulations comprising fentanyl and a cannabinoid receptor agonist
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CA2506615A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040213828A1 (en) * 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
JP2007509115A (ja) * 2003-10-21 2007-04-12 ソセイ・アール・アンド・ディー・リミテッド オピエートの増強のための非オピエートの使用
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2009103150A1 (en) * 2008-02-20 2009-08-27 Kevin David Smith Method for treating migraine headaches
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
AU2013305580A1 (en) * 2012-08-23 2015-04-09 Stuart L. Weg Anxiolytic composition, formulation and method of use
CN105073096A (zh) 2013-03-15 2015-11-18 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
WO2014169272A1 (en) 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
US9872841B2 (en) 2013-09-13 2018-01-23 National University Corporation Chiba University Application of R-ketamine and salt thereof as pharmaceuticals
AU2015301782B2 (en) 2014-08-13 2020-09-03 Janssen Pharmaceutica Nv Method for the treatment of depression
MX2017003366A (es) 2014-09-15 2018-02-01 Janssen Pharmaceutica Nv Regimenes de dosificacion y métodos especificos para el tratamiento de la depresión con el genotipo val66met (snp rs6265).
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US10179136B2 (en) 2015-06-19 2019-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10391102B2 (en) 2015-06-19 2019-08-27 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10555952B2 (en) 2015-06-19 2020-02-11 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10166240B2 (en) 2015-06-19 2019-01-01 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
JOP20200156A1 (ar) 2017-12-22 2022-10-30 Janssen Pharmaceuticals Inc إيسكيتامين لعلاج الاكتئاب
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
EP3934632A4 (de) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Esketamin zur behandlung von depression
EP3976012B1 (de) 2019-05-31 2024-03-20 Afyx Therapeutics A/S Intranasale verabreichung von ketamin an patienten mit cluster-kopfschmerzen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4334526A (en) * 1979-05-24 1982-06-15 Hamacher Edward N Method for administering a dissociative, unconscious type of anesthesia
US5132114A (en) * 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration

Also Published As

Publication number Publication date
DK0751766T3 (da) 2002-02-11
WO1995022965A3 (en) 1995-12-21
EP0751766B1 (de) 2001-10-17
MX9603633A (es) 1998-01-31
PT751766E (pt) 2002-04-29
JPH10500664A (ja) 1998-01-20
ES2165910T3 (es) 2002-04-01
ATE206913T1 (de) 2001-11-15
JP4729148B2 (ja) 2011-07-20
CA2184077C (en) 2007-12-11
DE69523295D1 (de) 2001-11-22
US5543434A (en) 1996-08-06
WO1995022965A2 (en) 1995-08-31
EP0751766A1 (de) 1997-01-08
CA2184077A1 (en) 1995-08-31

Similar Documents

Publication Publication Date Title
DE69523295T2 (de) Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DE69600307T2 (de) Beatmungsgerät zur Behandlung von Ateminsuffizienzen
DE69528247T2 (de) Regulierung der Wasserbehandlungsmitteldosierung, auf Basis von Betriebssystemspannungen
DE59300964D1 (de) Kontrollvorrichtung für den luftdruck von luftbereiften fahrzeugrädern.
DE69521521T2 (de) Mono- oder polyfunktionelle konjugate von polylysine
ATE359086T1 (de) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
ATE227127T1 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
ZA965938B (en) Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
HUP9802091A2 (hu) Idegátültetés pluripotens neuroepiteliális sejtek alkalmazásával
ATE297396T1 (de) Neue atropisomere von 2,3-disubstituierten-(5,6)- heteroarylkondensierten-pyrimidin-4-onen
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
DE9305147U1 (de) Trainingsgerät zur Behandlung von an Wahrnehmungsstörungen leidenden Patienten
LV11940A (lv) Melatonina pielietojums personu arstesanai kuras cies no zalu atkaribas
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
ATE218866T1 (de) Kombinationstherapie zur behandlung von aids
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin
FR2694500B1 (fr) Nébuliseur polyvalent pour le traitement des voies respiratoires.
DE29521125U1 (de) Gerät zur Applikation von Akupunkturnadeln
FR2718958B3 (fr) Dispositif pour le traitement du corps humain.
IT1271685B (it) Impiego dei polidesossiribonucleotidi nelle neuropati diabetiche
ES1029117Y (es) Mascarilla terapeutica desechable.
DE29514834U1 (de) Zahnpflegestift zum Pflegen und Säubern bzw. Vorbeugen von Zahnkrankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN